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ABSTRACT 
 Uterine leiomyomata (UL), commonly known as fibroids, are a major public 
health problem given their extreme prevalence (>70%), severity of associated symptoms, 
and indication for hysterectomies in women of reproductive age.  Familial aggregation 
and twin studies have provided evidence for a genetic component to predisposition to 
develop UL.  To date, a small number of genes involved in UL biology, including 
HMGA2, have been discovered through cytogenetic studies of the tumors.  HMGA2 is 
involved in recurrent translocations in UL and a TC repeat polymorphism in the gene is 
associated with UL diagnosis.  In this thesis, I investigate the possible role of the TC 
repeat in HMGA2 expression.  In 293T cells, the TC repeat number did not affect 
promoter activation, however, in the more relevant UL and myometrial cells, HMGA2
promoter activation was severely impaired and a definitive conclusion could not be made.  
Genome-wide linkage and association studies provide a promising, unbiased approach for 
revealing additional regions of the genome associated with UL.  In this thesis, I describe 
results from the first genome-wide linkage and association studies performed in white 
women affected with UL.  A genome-wide linkage study of affected white sister pairs 
revealed two significant linkage peaks in 10p11 (LOD=4.15) and 3p21 (LOD=3.73) with 
five suggestive peaks (LOD>2.00) in 2q37, 5p13, 11p15, 12q14, and 17q25.  A meta-
analysis of genome-wide association results in two independent cohorts of white women 
iv 
revealed a single nucleotide polymorphism (SNP) with genome-wide significance that is 
associated with UL diagnosis (rs4247357, P=3.05E-08, odds ratio (OR) =1.299).  The 
candidate SNP is located under the UL linkage peak at 17q25 and is in a large block of 
linkage disequilibrium (LD) which spans three genes:  fatty acid synthase (FASN), 
coiled-coil domain containing 57 (CCDC57) and solute carrier family 16, member 3 
(SLC16A3).  FAS transcripts and/or protein levels are up-regulated in various neoplasms 
and have been implicated in tumor cell survival.  By tissue microarray 
immunohistochemistry, we found FAS protein expression elevated three-fold in UL when 
compared to matched myometrial tissue implicating FASN as the first UL risk allele 
identified in white women by a genome-wide, unbiased approach. 
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CHAPTER 1: 
INTRODUCTION 
2 Uterine leiomyomata (UL), commonly known as fibroids, are benign tumors of 
the uterine myometrium.  Myometrium is made up of smooth muscle tissue and is the 
thickest layer of tissue in the uterus, flanked by the endometrium and the serosa.  UL are 
classified by tumor location within the myometrial layer:  subserosal, intramural, and 
submucosal.  They are hormonally dependent tumors and are not observed prior to 
puberty.  Estrogen, progesterone and other small growth factors (e.g., fibroblast growth 
factor and transforming growth factor-beta) promote tumor growth and they may regress 
at menopause.  UL are the most prevalent pelvic tumors in women, found in more than 
70% of women of reproductive age  and approximately 20-25% of women with UL 
exhibit symptoms (Buttram and Reiter 1981; Cramer and Patel 1990).  The most common 
symptoms of UL include abnormal uterine bleeding and pelvic pressure.  Many women 
with UL present with varying degrees of menorrhagia, or heavy menstrual bleeding.  If 
the tumors exert pressure on nearby organs, such as the bowel or bladder, women may 
also have problems with bowel movements and urinary frequency.  UL cause very 
serious reproductive issues and complications during pregnancy including recurrent 
miscarriage, infertility, premature labor, pain, bleeding, fetal malpresentation, and an 
increased risk of a cesarean section.  UL cause severe morbidity but not mortality, likely 
resulting in limited research funding and treatment options. 
The only essentially curative treatment for UL at this time is hysterectomy.  
Hysterectomies involve surgical removal of the entire uterus and leave the patient unable 
to bear children.  UL is the leading cause for hysterectomy in the United States, 
accounting for >30% of all hysterectomies and >40% of hysterectomies among women 
aged 45-64 years (Merrill 2008).  Annual health care costs of UL in the United States are 
3estimated at over 2 billion dollars, most of that cost associated with hysterectomies 
(Flynn, Jamison et al. 2006).  Most women suffering from these tumors are still in their 
childbearing years so this option is far from ideal.  A surgical treatment option that leaves 
the uterus intact, myomectomy, is also performed frequently.  A myomectomy is a 
surgical procedure in which individual UL are excised and removed from the uterus.  
Myomectomies are the only treatment for UL that is recommended for women who want 
to become pregnant; however, approximately half of all myomectomy patients will 
experience tumor recurrence and 10% will require additional surgery (Fedele, Parazzini 
et al. 1995). 
Less invasive therapies have been developed with limited success.  Gonadotropin-
releasing hormone (GnRH) analogue therapy is used to induce a low-estrogen 
environment in the body which decreases UL size.  The reduction in size is contingent on 
continuous exposure to the agonists, and tumors regrow rapidly when therapy has ceased.  
Long-term use of GnRHa has adverse side effects, specifically for bone density so 
GnRHa therapy is only used to decrease tumor size temporarily (Matta, Shaw et al. 
1989).  It is typically administered several months prior to surgery to improve anemia 
thought to be secondary to menorrhagia, and to allow for a more minimally invasive 
procedure.  Another option, MRI-guided focused ultrasound therapy (FUS), uses high 
frequency, high energy sound waves to denature proteins in UL cells, thereby causing 
cell death and tumor destruction.  An MRI scanner is used to locate and target UL in the 
uterus.  FUS is a low risk and noninvasive procedure, however, it is not widely available 
and its effect on future fertility is unknown (Hindley, Gedroyc et al. 2004).  Lastly, 
uterine artery embolization (UAE) is another minimally invasive option that involves 
4guiding a catheter from a small incision in the groin, through a leg artery, to the arteries 
in the uterus.  Embolic agents are delivered through the catheter to block blood supply to 
the tumors, which results in UL volume reduction (Hurst, Stackhouse et al. 2000).  These 
therapies do not eliminate tumors but instead relieve symptoms by reducing tumor size.  
They are much less invasive than hysterectomy, but are not curative and the impact on 
future fertility is unclear (Nowak 2001).  It is evident that more research into the 
underlying genetic causes of UL will be useful for developing more targeted and less 
invasive treatments. 
Rarely, estimated at 0.1%, UL may progress to their malignant counterpart, 
uterine leiomyosarcoma (LMS).  Expression profiling studies have been pursued in an 
attempt to understand the relationship between LMS and UL (Figure 1-1).  RNA from 
normal myometrium, UL and LMS was profiled using oligonucleotide microarrays in an 
attempt to identify genes whose expression levels distinguished the three groups of tissue.  
The clustering analysis found that normal myometrium and UL were more closely related 
to each other than to the malignant LMS (Quade, Wang et al. 2004).  However, in a 
follow-up study, a subgroup of UL with unusually cellular pathology and deletions in 1p 
segregated with the LMS samples, which indicates the profiles of these tumors are more 
closely related to the malignant tumors than to their benign counterparts and may 
represent the rare UL that develop into LMS (Christacos, Quade et al. 2006).  These 
profiling experiments have provided a tumor signature for UL and LMS while also 
highlighting the genetic heterogeneity in these tumors in that different subgroups of UL 
may exhibit distinct expression profiles that could identify important pathways in UL 
tumorigenesis and pathobiology. 
5Figure 1-1.  Hierarchial clustering illustrates myometrium and UL samples 
(in green) clustering separately from LMS (in red) and 1p- UL samples (in 
yellow).  Taken from (Christacos, Quade et al. 2006) 
6Genetic Risk Factors for UL 
 Several factors predispose women to develop UL.  Age, obesity, parity, and race 
have all been associated with prevalence of UL.  Black women are disproportionately 
affected by UL (Huyck, Panhuysen et al. 2008), with prevalence rates three to four times 
greater than white women even after controlling for other known risk factors (Marshall, 
Spiegelman et al. 1997).  Affected black women have more and larger UL in comparison 
to affected white women (Kjerulff, Langenberg et al. 1996).  The average age of 
diagnosis of black women is younger than white women, and black women are more 
likely to report severe UL symptoms (Huyck, Panhuysen et al. 2008).  Genetic events 
underlying this disparity have yet to be discovered and will undoubtedly provide major 
insights into UL biology.  Further, analyses of twin studies and familial aggregation 
indicate a genetic component to UL predisposition.  First degree relatives of affected 
probands have a 2.5-fold higher risk of developing UL and monozygotic twins' 
concordance for UL diagnosis is almost twice that of dizygotic twins' (Vikhlyaeva, 
Khodzhaeva et al. 1995; Treloar, Do et al. 1998).  Similarly, a study of a Finnish cohort 
found that monozygotic twins' concordance for being hospitalized for UL was twice that 
of dizygotic twins' (Luoto, Kaprio et al. 2000).  These findings support a genetic 
predisposition to develop UL. 
 The genetic lesion responsible for a Mendelian disorder involving UL, hereditary 
leiomyomatosis and renal cell cancer (HLRCC), has been identified through a genome-
wide linkage study.  HLRCC is caused by mutations in FH encoding fumarate hydratase, 
an enzyme involved in the citric acid cycle.  There are approximately 150 families with 
HLRCC and mutations in FH, which are inherited in an autosomal dominant manner 
7(Toro, Nickerson et al. 2003; Stewart, Glenn et al. 2008).  Interestingly, rats with 
mutations in the tuberous sclerosis 2 gene (TSC2) and German shepherd dogs with 
mutations in the folliculin gene (BHD) have very similar phenotypes of both UL and 
renal cell cancer (Everitt, Wolf et al. 1995; Lingaas, Comstock et al. 2003).  Variants in 
FH, TSC2 and BHD do not seem to play a major role in nonsyndromic UL in humans 
(Gross, Panhuysen et al. 2004). 
Genome-wide Genetic Studies 
 Genome-wide linkage and association studies have led to identification of many 
genes involved in both rare Mendelian and common diseases.  Linkage studies take 
advantage of related individuals and attempt to identify regions of the genome that are 
shared between affected family members.  Many families with the same disorder can be 
analyzed and any areas of the genome that are more commonly shared in affected 
individuals than would be expected by chance are likely to contain the disease-causing 
mutation.  Unfortunately, linkage studies, especially for diseases with significant genetic 
heterogeneity, often reveal candidate genomic regions that contain over a hundred genes 
and additional genotyping or sequencing is needed to locate the causal mutation.  
Genome-wide association studies (GWAS), however, usually identify candidate regions 
that contain only one or a few genes based on the size of the linkage disequilibrium 
block, making follow-up experiments potentially more straightforward.  In contrast to 
linkage studies, cohorts used in a GWAS are usually unrelated and much larger in order 
to provide enough power to detect associations. 
8 In a GWAS, single-nucleotide polymorphism (SNP) allele frequencies across the 
genome are analyzed and compared in cases and controls.  Variants that contribute to the 
disorder, or are linked to a variant that contributes to the disorder, are expected to have a 
higher frequency in cases.  Conversely, SNPs that do not play a role in affection status 
are expected to have equal frequencies in cases and controls.  In practice, it is unlikely to 
measure equal allele frequencies and by chance, a single GWAS will identify many SNPs 
with differential allele frequencies between cases and controls that are not truly 
associated with the disorder.  Because of this, a stringent statistical threshold is used to 
determine a true association from false positive results.  The threshold for a GWAS has 
been calculated as a p-value less than 5*10-8, which would be expected by chance only 
once in 20 GWASs (Altshuler, Daly et al. 2008).  Any SNPs that meet or exceed this 
threshold are considered significantly associated with the disorder, however, many true 
associations fall below this threshold and are overlooked.  SNPs with small effect sizes or 
very small minor allele frequencies require larger cohorts to reach the power needed to 
detect a significant association.  For most GWASs to date, study population size has been 
a significant limiting factor for power to detect associations. 
 Obtaining a substantial population depends largely on the prevalence of the 
disorder being tested and the ease of stratifying true cases from true controls.  UL is very 
common and most women with UL can be successfully identified using questionnaires.  
However, women who do not have UL are needed for controls and they are much harder 
to identify because  many women with UL are asymptomatic.  The only cohorts large 
enough to detect associations with UL were stratified based on questionnaires and power 
was lost due to misclassification of controls because many of the controls are probably 
9women with asymptomatic UL.  To date, only one genome-wide study has been 
performed for nonsyndromic UL.  A genome-wide association study in a Japanese cohort 
detected three loci significantly associated with UL diagnosis:  10q24.33, 22q13.1, and 
11p15.5 (Table 1-1) (Cha, Takahashi et al.).  Each locus encompasses several candidate 
genes, none of which have been implicated in UL biology previously and additional 
research is required to identify the pathogenetic sequences. 
 The primary aim of the thesis work presented here is to identify gene variants that 
predispose white women to develop UL.  We performed a genome-wide linkage study 
and two GWASs in three independent populations of white women.  A meta-analysis of 
the GWAS results revealed one SNP with a genome-wide significant association with 
UL.  This SNP is in a large block of linkage disequilibrium (LD) and is located under one 
of the UL linkage peaks in 17q25.3.  The candidate LD block contains three genes, fatty 
acid synthase (FASN), coiled-coil domain containing 57 (CCDC57) and solute carrier 
family 16, member 3 (SLC16A3).  CCDC57 and SLC16A3 are presently poorly 
characterized genes that have no prior association with UL or other tumors.  FASN, 
however, has been extensively studied and FAS protein expression is up-regulated in 
many tumor types (Menendez and Lupu 2007).  By immunohistochemistry, we found 
FAS expression to be elevated three-fold in UL compared to matched, normal 
myometrium tissue.  FASN is the first risk allele for UL identified in white women using 
a genome-wide, unbiased approach.  Finding additional pathogenetic sequences that 
predispose women to UL will provide insight into tumor development and could lead to 
screening strategies or improved management and therapy. 
10
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Recurrent Somatic Mutations in UL 
 Somatic gene variants involved in UL pathobiology have been discovered by 
cytogenetic analysis.  UL are independent, clonal lesions and approximately 40% have a 
non-random, tumor specific cytogenetic aberration with several subgroups recognized, 
including t(12;14)(q14-15;q23-24), del(7)(q22q32), trisomy 12, rearrangements involving 
6p21 and 10q22, and deletions of 1p and 3q (Figure 1-2) (Rein, Friedman et al. 1991), 
(Gross and Morton 2001).  Cytogenetic abnormalities have been correlated with tumor 
size, location, and histology, which indicate that genetic events play a fundamental role in 
UL biology (Brosens, Deprest et al. 1998),(Christacos, Quade et al. 2006).  For example, 
intramural UL have abnormal karyotypes more frequently than submucosal and subsersol 
UL (35% vs 12% and 29%) and UL with non-mosaic abnormal karyotypes are 
significantly larger than UL with normal karyotypes or mosaic abnormal karyotypes 
(Rein, Friedman et al. 1991).  Approximately 20% of UL with abnormal karyotypes have 
the most common translocation, t(12;14)(q14-15;q23-24).  These tumors are usually 
larger than tumors with a normal karyotype and tumors with del(7)(q22q32), the most 
common deletion found in UL.  Cytogenetic heterogeneity of UL underlies phenotypic 
differences and supports involvement of different pathways in tumor development. 
HMGA2 in UL 
Recent cytogenetic-based research of UL has focused on the most common 
subgroups.  Positional cloning of the pathogenetic sequences for two of the subgroups 
isolated high mobility group proteins (HMG), HMGA2 at 12q15 in the t(12;14) subgroup 
12
a b
c 
Figure 1-2.  Common cytogenetic subgroups found in UL:  a) 
t(12;14)(q14-15;q23-24), b) del(7)(q22q32), c) trisomy 12, d)
t(6;10)(q21;q22).  Taken from (Gross and Morton 2001). 
10    der(10) 6     der(6) 
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Figure 1-3.  Illustration of the HMGA2 a) gene structure and b) protein structure. 
14
and HMGA1 at 6p21 (Figure 1-3) (Ashar, Fejzo et al. 1995; Williams, Powell et al. 
1997).  Increased levels of HMGA1 and HMGA2 were found in tumors with 6p21 
rearrangements and t(12;14), respectively (Figure 1-4) (Williams, Powell et al. 1997; 
Gattas, Quade et al. 1999).  Trisomy 12 is also a major cytogenetic subgroup in UL and 
these results taken together suggest that increased expression of HMGA proteins is a key 
molecular event in UL pathobiology.  HMGA1 and HMGA2 are DNA architectural 
factors which can influence transcription by changing chromatin conformation 
(Grosschedl, Giese et al. 1994).  Both of these proteins have AT hook DNA-binding 
domains as well as protein binding domains that interact with transcription factors.  
HMGA2 plays a role in cell differentiation and proliferation in mesenchymal tissue, 
including myometrium, and abnormal expression of HMGA2 has been linked to several 
growth-related phenotypes.  Transgenic mice that do not express HMGA2 have a pygmy
phenotype (Zhou, Benson et al. 1995) while mice expressing a truncated form of the 
protein, which contains the DNA-binding domains but without the regulatory domains, 
develop an overgrowth phenotype with an unusually high frequency of lipomas (Battista, 
Fidanza et al. 1999).  Recently, a boy with a similar overgrowth phenotype was found to 
also express a truncated form of HMGA2, caused by a chromosomal inversion (Ligon, 
Moore et al. 2005).  Interestingly, several SNPs in the 3’ untranslated region (UTR) of 
HMGA2 have been identified in GWASs of variation in human height (Lettre, Jackson et 
al. 2008). 
As it is clear that somatic mutations in HMGA2 are involved in UL development 
and also that inherited mutations in HMGA2 can cause overgrowth phenotypes, a 
candidate gene association study with variants in HMGA2 was performed to determine if 
15
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inherited mutations in HMGA2 are responsible for predisposition to develop UL.  A TC 
repeat polymorphism in the 5’ UTR of HMGA2 was found to be associated with UL 
diagnosis in a population of affected white sister pairs (Hodge, K et al. 2009).  Although 
there are approximately 20 alleles of the TC repeat polymorphism in the population, only 
the allele representing 27 TC repeats was found to be associated with UL diagnosis 
(Figure 1-5).  The second aim of the thesis work presented here is to determine how this 
variant is affecting HMGA2 and risk of UL.  Because overexpression of HMGA2 is found 
in tumors with translocations near the gene and the TC27 repeat is in the 5' UTR, we 
decided to investigate the possibility that the TC27 repeat affects HMGA2 expression.  
One study used luciferase assays to show a significant decrease in HMGA2 promoter 
activation when the TC repeat polymorphism is removed (Figure 1-6) (Borrmann, 
Seebeck et al. 2003).  Also, using three TC repeat alleles corresponding to 1, 22, and 36 
TC repeats this group demonstrated increased promoter activation with increasing TC 
repeat number.  In an effort to investigate the role of the TC27 repeat, I also performed 
luciferase assays using the HMGA2 promoter with varying TC repeat alleles.  In 293T 
cells, there was no significant difference in promoter activation among seven of the most 
common TC repeat alleles, including TC27.  In UL and myometrium cell lines, there was 
a significant decrease in HMGA2 promoter activation and large variation in the results 
suggesting that these cell lines activate the HMGA2 promoter much differently than 293T 
cells.  An alternative method will need to be developed in order to evaluate the role of the 
TC27 repeat in HMGA2 promoter activation in the UL and myometrium cell lines. 
17
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 There is clear evidence for a genetic component to the predisposition to develop 
UL.  Identifying the variants that contribute to UL risk will undoubtedly provide 
invaluable insights into the biology of these tumors.  This thesis describes two such 
variants, FASN and HMGA2, which are associated with UL diagnosis and may contribute 
to UL predisposition in white women.  Further study is needed to elucidate the specific 
role of these variants in UL pathobiology and to evaluate them as possible targets for 
novel UL therapies.  
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ABSTRACT 
 Uterine leiomyomata (UL), the most prevalent pelvic tumors in women of 
reproductive age, pose a major public health problem given their high frequency, 
associated morbidities and most common indication for hysterectomies.  A genetic 
component to UL predisposition is supported by analyses of ethnic predisposition, twin 
studies, and familial aggregation.  A genome-wide SNP linkage panel was genotyped and 
analyzed in 261 white UL sister pair families from the Finding Genes for Fibroids study 
(FGFF).  Two significant linkage regions were detected in 10p11 (LOD=4.15) and 3p21 
(LOD=3.73) while five additional linkage regions were identified with LOD scores >2.00 
in 2q37, 5p13, 11p15, 12q14 and 17q25.  Genome-wide association studies were 
performed in two independent cohorts of white women and a meta-analysis was 
conducted.  One SNP was identified with a p-value that reached genome-wide 
significance (rs4247357, P = 3.05E-08, odds ratio (OR) = 1.299).  The candidate SNP is 
under a linkage peak and in a block of linkage disequilibrium in 17q25.3 which spans the 
genes fatty acid synthase (FASN), coiled-coil domain containing 57 (CCDC57) and solute 
carrier family 16, member 3 (SLC16A3).  By tissue microarray immunohistochemistry, 
we found FAS protein expression elevated (3-fold) in UL when compared to matched 
myometrial tissue.  FAS transcripts and/or protein levels are up-regulated in various 
neoplasms and implicated in tumor cell survival.  FASN represents the first UL risk allele 
identified in white women by a genome-wide, unbiased approach and opens a path to 
management and potential therapeutic intervention.  
26
INTRODUCTION 
 Uterine leiomyomata (UL), commonly known as fibroids, are benign tumors of 
the uterine myometrium.  They represent the most prevalent pelvic tumors in women, 
found in more than 70% of women of reproductive age (Cramer and Patel 1990).  
Approximately 20-25% of women with UL exhibit symptoms including menorrhagia, 
infertility, pelvic pain and a range of complications during pregnancy (Buttram and 
Reiter 1981).  The leading cause for hysterectomy in the United States, UL account for 
>30% of all hysterectomies and >40% of hysterectomies among women aged 45-64 years 
(Lepine, Hillis et al. 1997).  Annual health care costs of UL are estimated at over two 
billion dollars, most of that cost associated with hysterectomies (Flynn, Jamison et al. 
2006).  Although UL pose a major public health problem, little is known about the 
molecular basis for these tumors and treatment options are limited. 
 Genes involved in UL have been discovered by cytogenetic analysis.  
Approximately 40% of UL have a non-random cytogenetic aberration and several 
subgroups are recognized, including t(12;14)(q14-15;q23-24), del(7)(q22q32), trisomy 
12, rearrangements involving 6p21 and 10q22, and deletions of 1p and 3q (Rein, 
Friedman et al. 1991; Gross and Morton 2001).  Cytogenetic abnormalities have been 
correlated with tumor size, location, and histology, which indicate that genetic events 
play a fundamental role in UL biology (Rein, Friedman et al. 1991; Brosens, Deprest et 
al. 1998; Christacos, Quade et al. 2006).  Cytogenetic heterogeneity of UL underlies 
phenotypic differences and supports involvement of different pathways in tumor 
development. 
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Several factors predispose women to develop UL.  Age, obesity, parity, and race 
have all been associated with prevalence of UL.  Black women are disproportionately 
affected by UL (Huyck, Panhuysen et al. 2008), with incidence and prevalence rates at 
least three times greater than that in white women even after controlling for other known 
risk factors (Marshall, Spiegelman et al. 1997).  Further, analyses of twin studies and 
familial aggregation indicate a genetic component to UL predisposition; first degree 
relatives of affected women have a 2.5-fold higher risk of developing UL and 
monozygotic twins' concordance for UL diagnosis is almost twice that of dizygotic twins' 
(Vikhlyaeva, Khodzhaeva et al. 1995; Treloar, Do et al. 1998).  Similarly, a study of a 
Finnish cohort found that monozygotic twins' concordance for being hospitalized for UL 
was twice that of dizygotic twins' (Luoto, Kaprio et al. 2000).  These findings support a 
genetic predisposition to develop UL but no genome-wide study of UL in white women 
has been reported.  Several candidate gene association studies have been performed with 
limited success, although variants in the 5’ UTR of HMGA2, a gene involved in recurrent 
cytogenetic aberrations of UL and known to play a primary role (Schoenberg Fejzo, 
Ashar et al. 1996), have been associated with UL diagnosis in a cohort of white sister 
pairs (Hodge, K et al. 2009).  Finding additional pathogenetic sequences that predispose 
women to UL will provide insight into tumor development and could lead to screening 
strategies or improved management and therapy. 
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RESULTS 
Linkage Study 
Linkage analysis with the Finding Genes for Fibroids (FGFF) population (see 
Methods) revealed two peaks with highly significant genome-wide LOD scores (>3.6) 
and five peaks with suggestive LOD scores (>2.0) (Figure 2-1).  The highest LOD scores 
found are at 10p11 (LOD=4.15) and at 3p21 (LOD=3.73).  Both linkage regions are 
around 35 Mb and contain hundreds of genes.  Of note, HMGA2 resides within the 
linkage region at 12q14 with a suggestive LOD score of 2.62 (Figure 2-2).  
Association Analyses and Meta-Analysis 
Genome-wide association studies (GWAS) were undertaken with two 
independent cohorts of white women, the Women’s Genome Health Study (WGHS) 
cohort and an Australian cohort (see Methods).  Analysis of the WGHS cohort revealed 
45 SNPs with p-values less than 10-4 (Table 2-1).  Although none of the p-values from 
this analysis are considered significant to identify a genome-wide association, the 
quantile-quantile plot of the results provides evidence that there are more SNPs with 
small p-values than expected by chance (Figure 2-3a).  In the Australian analysis, 25 
SNPs were identified with p-values less than 10-4 and the quantile-quantile plot reveals a 
small increase in low p-values although it is less striking than the WGHS results (Table 2-
2, Figure 2-3b).  Meta-analysis was performed on the set of 344,655 genotyped SNPs 
from the WGHS and Australian cohorts using an inverse-variance weighted method in 
METAL (http://www.sph.umich.edu/csg/abecasis/Metal/index.html).  One SNP, 
rs4247357, reached genome-wide significance and is considered significantly associated 
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Figure 2-2. FGFF linkage peak at 12q14 with HMGA2 circled in red.   
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Table 2-1.  WGHS genome-wide association analysis results (P<10-4) 
CHR SNP Position (bp) F_A F_U A2 CHISQ P-value 
1 rs2268179 22287371 0.2091 0.1588 C 23.37 1.34E-06
17 rs4247357 77760277 0.467 0.4014 C 22.64 1.95E-06
17 rs6502057 77675348 0.4628 0.3977 G 21.78 3.06E-06
15 rs2903332 78340261 0.3124 0.2542 G 21.75 3.10E-06
17 rs11077969 77678921 0.4655 0.4017 G 21.31 3.91E-06
17 rs7502078 77725167 0.4678 0.4044 C 21.24 4.04E-06
17 rs7213172 77678991 0.4657 0.4023 A 21.16 4.23E-06
17 rs8080423 77695567 0.4672 0.4039 A 21.1 4.36E-06
17 rs7406163 77679677 0.4772 0.4128 A 21.06 4.46E-06
17 rs7221544 77680625 0.4664 0.4042 A 20.41 6.26E-06
9 rs11139665 84451020 0.05295 0.03042 A 19.98 7.84E-06
22 rs732110 26345321 0.1166 0.08168 A 19.73 8.90E-06
5 rs30523 132138941 0.1516 0.1125 G 18.71 1.52E-05
1 rs6693503 19859880 0.4135 0.3555 G 18.61 1.61E-05
14 rs1951054 25147247 0.3004 0.3575 A 18.33 1.86E-05
1 rs2012235 68685342 0.2332 0.2866 A 18.11 2.09E-05
4 rs2333255 176819759 0.4289 0.4874 C 17.55 2.80E-05
1 rs12563321 26539088 0.2554 0.2074 G 17.5 2.87E-05
1 rs9729637 5468038 0.09182 0.06265 C 17.45 2.95E-05
14 rs1257670 98562725 0.3394 0.2867 A 17.06 3.63E-05
1 rs12117956 27370168 0.305 0.3598 A 16.89 3.97E-05
9 rs7855598 137454075 0.2262 0.1813 A 16.84 4.06E-05
1 rs4846689 219444057 0.1156 0.0832 A 16.71 4.36E-05
6 rs6903101 138567539 0.04625 0.02687 A 16.69 4.39E-05
17 rs917538 14975565 0.4538 0.3978 C 16.6 4.61E-05
1 rs6687674 27409687 0.362 0.4182 G 16.58 4.67E-05
14 rs2284230 77085649 0.175 0.2217 G 16.5 4.88E-05
10 rs3824700 26395911 0.4953 0.4388 A 16.48 4.92E-05
11 rs7945105 131162979 0.3653 0.4212 G 16.48 4.93E-05
10 rs1521032 26393597 0.4946 0.4385 A 16.3 5.41E-05
1 rs10902742 26548843 0.2372 0.1923 C 16.13 5.91E-05
10 rs11593128 26392957 0.4946 0.4385 A 16.09 6.04E-05
10 rs3936497 28619974 0.1034 0.0734 A 16 6.34E-05
1 rs1454356 189400411 0.3495 0.4044 A 15.97 6.42E-05
9 rs1556047 112083819 0.5121 0.4565 A 15.86 6.83E-05
2 rs12692335 7524145 0.2483 0.203 G 15.84 6.90E-05
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Table 2.1 (Continued) 
8 rs10955841 119015721 0.3718 0.3198 A 15.67 7.52E-05
1 rs9786944 5471098 0.08914 0.06186 G 15.5 8.24E-05
6 rs6926282 112968480 0.128 0.09509 G 15.43 8.55E-05
21 rs13049184 21818485 0.4448 0.4998 G 15.4 8.70E-05
12 rs12579612 93189923 0.2426 0.1984 A 15.39 8.75E-05
10 rs1521033 26422356 0.494 0.4395 G 15.36 8.89E-05
6 rs627240 81042603 0.3834 0.4387 C 15.33 9.04E-05
15 rs11636483 96937674 0.2507 0.206 A 15.25 9.44E-05
16 rs16953111 78954425 0.09987 0.07114 G 15.17 9.83E-05
33
a 
b
Figure 2-3.  Quantile-quantile plot of (a) WGHS GWAS results and (b) Australian 
GWAS results.  P-values observed in the studies are compared to p-values expected 
under the null hypothesis. 
WGHS =1.0221 
Australian =1.0231 
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Table 2-2.  Australian genome-wide association analysis results (P<10-4) 
CHR SNP Position (bp) F_A F_U A2 CHISQ P-value 
8 rs10504743 82951580 0.04752 0.09918 G 20.43 6.18E-06
1 rs10779614 212656537 0.1777 0.2574 G 19.84 8.43E-06
1 rs6703314 104976389 0.3244 0.2397 A 19.29 1.13E-05
12 rs6539579 80696724 0.2562 0.3418 A 18.7 1.53E-05
3 rs4128782 89320422 0.468 0.5607 G 18.57 1.64E-05
7 rs1829993 77698210 0.469 0.5615 G 18.49 1.71E-05
5 rs10515600 147316068 0.3089 0.3975 C 18.45 1.74E-05
17 rs11079098 49220927 0.3295 0.4189 A 18.28 1.90E-05
2 rs750132 218548607 0.1508 0.09262 G 17.52 2.84E-05
17 rs3785655 14189892 0.2996 0.3844 T 17.15 3.46E-05
6 rs9389508 137842904 0.1405 0.08525 C 16.87 4.00E-05
18 rs4542757 48452722 0.3068 0.391 T 16.72 4.32E-05
7 rs6967325 77678568 0.407 0.323 A 16.56 4.72E-05
10 rs2082988 128254551 0.3409 0.4262 G 16.54 4.77E-05
20 rs6116201 4033758 0.1498 0.218 A 16.47 4.93E-05
20 rs10485664 38064192 0.2293 0.1607 A 16.48 4.93E-05
17 rs1859906 14191413 0.3688 0.4549 G 16.47 4.95E-05
9 rs11144978 78415148 0.3089 0.232 A 16.36 5.25E-05
1 rs1808973 112289357 0.4122 0.4975 T 15.83 6.93E-05
7 rs798332 77746864 0.3946 0.3131 T 15.78 7.11E-05
3 rs7429534 89273999 0.3564 0.4402 C 15.74 7.28E-05
6 rs6570048 136240287 0.4287 0.5131 T 15.41 8.64E-05
1 rs3006009 242697070 0.3533 0.4361 T 15.41 8.65E-05
1 rs11120315 212653320 0.1126 0.1721 C 15.36 8.90E-05
12 rs12228394 19482075 0.01756 0.04836 C 15.27 9.32E-05
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with UL status (Table 2-3).  Five additional SNPs in the same location on chromosome 
17 were identified with p-values less than 10-6.  The quantile-quantile plot of the meta-
analysis results clearly shows that this group of SNPs have lower p-values than would be 
expected under the null hypothesis (Figure 2-4).  The candidate SNPs on chromosome 17 
are located in a large linkage disequilibrium (LD) block which contains three genes, fatty 
acid synthase (FASN), coiled-coil domain containing 57 (CCDC57) and solute carrier 
family 16, member 3 (SLC16A3) (Figure 2-5, Figure 2-6).  Interestingly, this LD block 
lies under the FGFF linkage peak at 17q25 (Figure 2-7).
FAS Protein Expression 
 Little is known about CCDC57 or SLC16A3, however, FAS has been associated 
in several cancers and is often up-regulated in cancer tissue (Menendez and Lupu 2007).  
In order to investigate this finding in UL, we stained UL and myometrial tissue with a 
FAS antibody.  FAS immunostaining revealed a three-fold increase in FAS expression in 
UL compared to matched, normal myometrium (Figure 2-8).  An increase in UL FAS 
expression was seen in 25 out of 33 (~76%) matched samples (Figure 2-9).  Stratifying 
matched samples by rs4247357 genotype shows an increase in FAS expression in 
myometrium and UL with the major allele compared to the minor allele.  Increased 
expression in myometrium samples with the major allele is not statistically significant but 
the increase in UL with the major allele is about two-fold and is significant (Figure 2-
10a).  When all UL samples are combined, the same pattern emerges but the increase in 
FAS expression in UL with the major allele is about 50% higher than UL with the minor 
allele (Figure 2-10b).  Interestingly, in both matched and combined analyses, FAS  
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Figure 2-4.  Quantile-quantile plot of meta-analysis results.  P-values observed in the 
study are compared to p-values expected under the null hypothesis.  Top SNPs in 
17q25.3 region are circled in green. 
	
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Figure 2-5.  Candidate region on chromosome 17 containing significantly 
associated markers.  P-values for WGHS genotyped SNPs are indicated by 
diamonds, p-values for WGHS imputed SNPs are indicated by circles and p-
values for SNPs included in the meta-analysis are indicated by triangles. 
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Figure 2-7.  FGFF linkage peak at 17q25 with FASN circled in red. 
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Figure 2-10.  FAS protein expression in myometrium and UL from (a) matched 
samples and (b) all samples stratified by rs4247357 genotype. 
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expression in both myometrium and UL samples heterozygous for major and minor 
alleles was at a level between that of samples homozygous for either the major or minor 
alleles. 
mRNA Expression 
 Analysis of mRNA expression levels in myometrium and UL by microarray of 
genes under the linkage peak on chromosome 17 revealed no genes with significant 
differential expression between women with the major (n=6) and minor alleles (n=3) of 
rs4247357.  FASN, CCDC57 and SLC16A3 were found not to be expressed at a 
detectable level in the myometrium and UL samples analyzed.  However, a more 
comprehensive analysis of 54,000 probes across the genome revealed several genes 
significantly upregulated and downregulated in UL with the minor allele compared to UL 
with the major allele (Table 2-4). 
 Targeted mRNA expression analysis by qPCR detected no substantial expression 
differences of matched myometrium and UL samples for FASN, CCDC57, SLC16A3 and 
three genes located directly nearby but outside of the candidate LD block, DUS1L, 
CSNK1D and NARF (Figure 2-11a).  Expression of FASN, CCDC57 and SLC16A3 is 
slightly higher in the matched UL samples but expression of DUS1L and NARF is also 
higher in the matched UL samples and the variation between samples is relatively large.  
It is unclear whether this expression difference has biological significance; however, it is 
clear that mRNA expression of FASN between myometrium and matched UL samples is 
not concordant with FAS protein expression as the same samples were used in both 
studies.  This finding is not surprising as the correlation between mRNA and protein 
levels can be poor, with some studies finding that only 40% of variation in protein.   
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Table 2-4.  mRNA of genes found to be upregulated or downregulated in UL 
with the minor allele of rs4247357 compared to UL with the major allele. 
Gene Location Fold Change Direction P-value 
MMS19 10q24.1 1.558 up 7.45E-07 
SH3BP4 2q37.2 1.804 down 8.42E-07 
TUBB2A 6p25.2 2.658 down 1.86E-06 
NLN 5q12.3 1.617 down 2.19E-06 
FAM126A/DRCTNNB1A 7p15.3 1.699 down 6.49E-06 
STX7 6q23.2 2.014 down 6.88E-06 
PDS5B/KIAA0979 13q13.1 1.753 down 7.25E-06 
CR613961 1p36.11 2.655 down 7.96E-06 
CR749816 1p21.2 1.817 down 8.49E-06 
PMEPA1 20q13.31 2.284 down 1.16E-05 
MAP3K7IP3 Xp21.2 2.581 down 1.17E-05 
HOOK3 8p11.21 1.650 down 1.46E-05 
C12orf47 12q24.12 1.728 up 1.47E-05 
ANKRD27 19q13.11 1.870 down 1.55E-05 
RAB6C 2q21.1 1.407 down 1.71E-05 
C6orf162 6q15 1.585 up 1.82E-05 
PICALM 11q14.2 1.884 down 1.83E-05 
c3orf19 3p25.1 1.310 up 2.07E-05 
ZSIG13/FZD4 11q14.2 2.527 down 2.15E-05 
PIAS1 15q23 1.685 up 2.36E-05 
FADS1 11q12.2 1.948 down 2.38E-05 
PHF21A/KIAA1696 11p11.2 1.343 up 2.45E-05 
RBM15 1p13.3 1.810 down 2.65E-05 
DIS3 13q22.1 1.565 down 2.78E-05 
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b
c 
Figure 2-11.  mRNA expression by qPCR of FASN, CCDC57, SLC16A3 and three 
genes in direct proximity (DUS1L, CSNK1D, NARF) in (a) myometrium and matched 
UL samples (b) myometrium with the major (AA) and minor (CC) allele of rs4247357 
and (c) UL with the major (AA) and minor (CC) allele of rs4247357. 
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expression can be explained by mRNA expression (de Sousa Abreu, Penalva et al. 2009).  
Also, expression of all six genes was higher in myometrium and UL with the minor allele 
compared to myometrium and UL with the major allele (Figure 2-11b, c).  Similarly, it is 
unclear if this difference is of relevance due to the fact that it is relatively small, is 
observed for every gene analyzed, and the variation between samples is relatively large. 
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DISCUSSION 
The FGFF linkage study provides evidence for a genetic contribution to UL 
development as seen by two significant linkage peaks and several other suggestive peaks.  
Although candidate genes have yet to be identified under five peaks, one gene 
prominently recognized in UL biology, HMGA2, is located under the peak on 12q14.  
Translocations involving HMGA2 are frequently found in UL tumors (Schoenberg Fejzo, 
Ashar et al. 1996).  Additionally, a recent study using the FGFF population found a 
significant association between UL status and a variant in the 5’ UTR of HMGA2 
(Hodge, K et al. 2009).  The discovery of several linkage peaks illustrates the genetic 
heterogeneity of these tumors and is consistent with the hypothesis that a variety of genes 
and pathways participate in UL development.  Additionally, a genome-wide association 
study in a Japanese cohort found three loci significantly associated with UL diagnosis:  
10q24.33, 22q13.1, and 11p15.5 (Cha, Takahashi et al.).  These loci are not associated 
with UL in our cohorts of white women, and our locus at 17q25.3 was not identified in 
the Japanese study supporting genetic heterogeneity in UL predisposition between ethnic 
groups. 
Association analyses using the WGHS and Australian cohorts may have identified 
more precisely the locus underlying the linkage signal on chromosome 17.  Six SNPs on 
chromosome 17 were in the top associated SNPs in the WGHS analysis and proved 
significantly associated with UL status after meta-analysis of the WGHS and Australian 
cohorts.  These SNPs are in LD across FASN, CCDC57 and SLC16A3.  At this time it 
cannot be determined if any of these markers are the causal SNP associated with UL 
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affection status or if they are in LD with the causal SNP.  SLC16A3 is a member of the 
proton-linked monocarboxylate transporter family that facilitates transport of substrates 
across the plasma membrane.  CCDC57 contains a coiled coil domain and may function 
by binding DNA.  SLC16A3 and CCDC57 are minimally characterized, making it 
difficult to conjecture about their possible involvement in UL development.  Neither of 
these genes nor proteins has been indicated in disease and our qPCR studies did not 
reveal any unusual mRNA expression in UL.  Conversely, we found a large increase in 
FAS expression in UL compared to matched myometrial tissue.  FAS has been 
extensively characterized and is the enzyme responsible for de novo fatty acid synthesis.  
It is most highly expressed in hormone-sensitive cells (Kusakabe, Maeda et al. 2000) and 
has been found to be regulated at both transcriptional and post-transcriptional levels.  
Sterol regulatory element binding transcription factor 1 (SREBP-1) is the primary 
transcription factor of FASN and is activated downstream of growth factor and hormone 
receptors (Eberle, Hegarty et al. 2004).  FAS protein is stabilized by USP2a, an 
isopeptidase that deubiquitinates and prevents protein degradation.  USP2a is 
overexpressed in some prostate tumors with high FAS expression (Graner, Tang et al. 
2004) and could explain discordant levels of FASN mRNA and FAS protein levels in our 
UL samples. 
Upregulation of FAS has been discovered in many cancers including prostate, 
breast, and colon (Alo, Visca et al. 1999; Rossi, Graner et al. 2003; Ogino, Nosho et al. 
2008).  In some cancers, upregulation of FAS is correlated with poor prognosis, cancer 
progression or specific tumor types (Liu, Liu et al.).  Inhibitors of FAS lead to growth 
arrest and apoptosis in cancer cell lines with relatively minor effects in corresponding 
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normal cells (Pizer, Jackisch et al. 1996; Pizer, Chrest et al. 1998).  Many studies have 
found a connection between FAS and the PI3K/Akt signaling pathway, one of the most 
frequently disregulated pathways in human cancers (Van de Sande, De Schrijver et al. 
2002; Porstmann, Griffiths et al. 2005).  Inhibitors of FAS used in breast cancer animal 
models and several xenograft models have resulted in delayed development and slowed 
progression of tumors (Alli, Pinn et al. 2005; Lupu and Menendez 2006).  Knocking 
down FASN mRNA causes a host of changes in gene expression and protein activity in 
the cell (Knowles and Smith 2007) making it clear from these and many more studies that 
the role of FAS in neoplasia is much more complicated and probably more important than 
simply providing fatty acids.  Although it remains to be known how the minor allele of 
the candidate LD block influences FASN and UL development, overexpression of FAS in 
these UL samples and the overwhelming evidence that FAS is a metabolic oncogene 
makes it a compelling candidate gene for UL development for which clinical trials with 
inhibitors might be warranted. 
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MATERIALS AND METHODS 
Finding Genes for Fibroids Linkage Analysis 
Sister pairs affected with UL were recruited for the “Finding Genes for Fibroids” 
(FGFF) study.  Approximately 385 sister pairs were consented for this project.  Both 
sisters have medical record confirmed UL, provide a blood sample and complete a 
questionnaire on clinical, reproductive, sexual, and family history relating to UL.  Other 
family members of the sisters also contributed samples and completed questionnaires.  
Study participants were recruited under an IRB protocol approved by the Partners 
HealthCare System Human Research Committee.  DNA was isolated using a Puregene 
Blood Kit (Gentra, Minneapolis, MN) and the DNA, pedigree information, and UL 
affection status were provided to the genotyping core at The Center for Inherited Disease 
Research (CIDR) at Johns Hopkins University.  A whole genome SNP linkage scan was 
performed using Illumina’s Human Linkage-12 Genotyping BeadChip (San Diego, CA).  
Two families with multiple Mendelian inconsistencies were excluded in addition to 14 
SNP markers due to low quality genotype calls. 
Linkage analysis was performed with Genehunter software using samples from 
self-reported white sister pairs and family members, which comprised 261 families with a 
total of 1103 individuals.  The minor allele frequency (MAF) of each SNP was calculated 
using the genotype information from one sister in each family.  SNPs were pruned using 
PLINK software (Purcell, Neale et al. 2007) based on an r2 of 0.2 resulting in a total of 
4,196 SNPs for the final analysis.  Sib-pair analysis was carried out with UL status as the 
phenotype and significant linkage with UL was defined as a LOD score greater than 3.6.  
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Despite particular interest in recruitment of black women, the FGFF study has not yet 
reached an appropriate number of sister pairs for this important analysis. 
Women’s Genome Health Study Association Study 
The Women’s Genome Health Study (WGHS) (Ridker, Chasman et al. 2008) is a 
prospective cohort of female North American health care professionals representing 
participants in the Women’s Health Study (WHS) who provided a blood sample at 
baseline and consent for blood-based analyses.  Participants in the WHS were 45 years of 
age or older at enrollment and free of cardiovascular disease, cancer or other major 
chronic illness.  Additional information related to health and lifestyle were collected by 
questionnaires throughout the WHS trial and continuing observational follow-up.  WHS 
participants were asked if they had ever been diagnosed with UL, their age at diagnosis, 
whether their mother or sister had ever been diagnosed with UL and their history of 
hysterectomy. 
Genotyping in the WGHS sample was performed using the HumanHap300 Duo 
‘‘+’’ chips or the combination of the HumanHap300 Duo and iSelect chips (Illumina, San 
Diego, CA) with the Infinium II protocol.  In either case, the custom SNP content was the 
same; these custom SNPs were chosen without regard to minor allele frequency (MAF) 
to saturate candidate genes for cardiovascular disease as well as to increase coverage of 
SNPs with known or suspected biological function, e.g. disease association, non-
synonymous changes, substitutions at splice sites, etc.  For quality control, all samples 
were required to have successful genotyping using the BeadStudio v. 3.3 software 
(Illumina) for at least 98% of the SNPs.  A subset of 23,294 individuals were identified 
with self-reported European ancestry, verified on the basis of multidimensional scaling 
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analysis of identity by state using 1,443 ancestry informative markers in PLINK v. 1.06 
(Purcell, Neale et al. 2007).  The final dataset of these individuals included SNPs with 
MAF >1%, successful genotyping in 90% of subjects, and deviations from Hardy-
Weinberg equilibrium not exceeding p=10-6.  Among the final 23,294 individuals of 
verified European ancestry, genotypes for a total of 2,608,509 SNPs were imputed from 
the experimental genotypes and LD relationships implicit in the HapMap r. 22 CEU 
samples.  Imputed SNPs were used to define the region of LD surrounding association 
signals found with genotyped SNPs. 
UL status, age at diagnosis, mother or sister UL status, and history of 
hysterectomy were ascertained by recall in the 2009 WGHS questionnaire.  UL cases and 
controls from WGHS were stratified based on these four variables in an attempt to 
identify women most and least likely to have a genetic basis for UL.  Any participant 
who answered “not sure” for UL status or mother/sister UL status was excluded from the 
analysis.  Participants were also excluded who reported an age of UL diagnosis at less 
than 20 years or at greater than 70 years.  Cases included women who answered “yes” for 
UL status, “yes” for their mother or sister UL status, and either had an age of diagnosis 
under 40 years or had a hysterectomy.  Controls included women who answered “no” to 
UL status, mother/sister UL status and who had not had a hysterectomy.  Women not 
qualifying for either of these groups were excluded from the analysis.  Following 
stratification there were 746 cases and 4,487 controls.  Association analysis was 
performed on the set of 339,187 genotyped SNPs in PLINK using the standard 
case/control test and p-values less than 5×10-8 were considered significant. 
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Australian Cohort Association Study 
Individuals comprising the cohort from the Queensland Institute of Medical 
Research (QIMR) were women who had been genotyped previously on Illumina’s 317K, 
370K or 610K SNP platforms as part of a larger collection of genome-wide association 
studies conducted at QIMR (Painter, Anderson et al.; Medland, Nyholt et al. 2009).  Case 
samples (n = 484) were selected from amongst women originally recruited into a study of 
genetic factors underlying endometriosis (Treloar, Wicks et al. 2005) and a twin study of 
gynecological health (Treloar, Do et al. 1999).  For both studies, women had completed 
questionnaires on various aspects of reproductive health, and cases had answered ‘yes’ to 
the ‘uterine fibroids’ option of the question “Have you ever had any of the following 
conditions?”  Controls (n = 610) were taken from amongst twin pairs from the 
gynecological health study where both sisters had answered ‘no’ to the question on 
uterine fibroids (one sample per twin pair).  A standard case/control association analysis 
was performed on the set of 269,629 SNPs genotyped in common between all samples 
and passing all QC metrics in PLINK (Purcell, Neale et al. 2007).  Approval for the 
studies was granted by the Human Research Ethics Committee at QIMR and the 
Australian Twin Registry.  All gene annotations and base pair positions are derived from 
the human genome sequence hg18 (NCBI build 36.1). 
Demographics 
Demographics of the FGFF, WGHS and Australian cohorts were considered, 
focusing on variables most relevant to UL diagnosis.  In the WGHS and Australian 
cohorts, cases have a slightly higher BMI and have decreased stature compared to 
controls although the difference is not significant in the WGHS population (defined as a 
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P >0.05) (Table 2-5).  Previous studies have also reported a correlation with UL diagnosis
and a higher BMI (Kharazmi, Fallah et al. 2007; Takeda, Sakata et al. 2008).  WGHS and 
Australian cases also have a younger age at menarche which could be expected as UL are 
hormone dependent neoplasms and a younger age at menarche is associated with longer 
reproductive years and additional years of hormone exposure.  Lastly, although 
Australian cases were not selected based on a history of hysterectomy, UL cases have a 
very significant increase in hysterectomy prevalence reflecting the fact that UL are the 
leading cause for this surgery.  Overall, demographics of the WGHS and Australian 
cohorts were unremarkable and confirmed previously reported UL associations. 
FAS Immunohistochemistry 
 Fatty acid synthase (FAS) expression in UL and myometrium tissue was analyzed 
by immunohistochemistry of tissue microarrays (TMAs) consisting of paraffin embedded 
formalin fixed tissue sections from 200 women, 36 myometrium samples and 337 UL 
samples.  The TMA includes matched myometrium and UL samples from 33 women.  
Two TMAs were constructed using sections from different areas of the same tissue.  
DNA corresponding to 106 tissue sections was isolated and used to genotype rs4247357 
in CCDC57.  Immunostaining was performed on both TMAs using the primary 
monoclonal antibody against FAS (Transduction Laboratories, Lexington, KY) at a 1:100 
dilution and hematoxylin as a counterstain.  Each core was evaluated for the ratio of stain 
to counterstain to account for variable cellularity in tissue sections.  The average 
stain/counterstain ratio was determined and compared across myometrium and UL 
samples and also across samples with the major and minor allele of rs4247357. 
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mRNA Expression Analysis by Microarray 
RNA was isolated from myometrium and 28 UL from 14 women.  Gene 
expression levels were analyzed using the Affymetrix GeneChip system U133 plus 2.0.  
DNA was also extracted and used to genotype rs4247357 in CCDC57.  Gene expression 
levels were compared between women with the major and minor allele of rs4247357. 
Targeted mRNA Expression Analysis by qPCR 
RNA was isolated from myometrium and 20 UL from 12 women, six with the 
major allele of rs4247357 and six with the minor allele.  cDNA was synthesized and used 
in qPCR assessments of FASN, CCDC57, SLC16A3, DUS1L, CSNK1D, and NARF.  
Gene products were normalized to the internal reference gene, GAPDH, and normalized 
ratios were compared across myometrium and UL samples and across women with the 
major and minor allele of rs4247357. 
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ABSTRACT 
 Uterine leiomyomata, commonly known as fibroids, are the most prevalent tumor 
in women of reproductive age.  Genes implicated in UL biology have been identified 
through cytogenetic studies of the tumors and candidate gene association studies.  One 
such gene, HMGA2, is involved in the most common translocation found in UL, 
t(12;14)(q14-15;q23-24), which results in its overexpression.  A candidate gene 
association study of 18 markers across HMGA2 revealed a significant association of a TC 
repeat polymorphism, corresponding to 27 TC repeats, in the 5' UTR with UL diagnosis.  
One published report describing the HMGA2 promoter found the TC repeat 
polymorphism to be crucial for promoter activation.  We investigated the role of the 
TC27 repeat in promoter activation using luciferase assays in 293T, UL and myometrial 
cell lines.  No difference in promoter activation was found across seven common TC 
repeat polymorphisms, including TC27, in 293T cells.  HMGA2 promoter activation was 
greatly impaired in UL and myometrial cells which resulted in weak luminescence and 
large variability.  The variability in this experiment prevented us from making a 
conclusion about the role of the TC27 repeat in UL and myometrial cells.  Future work 
will focus on developing an alternative method of transfection in UL and myometrial 
cells to generate more robust luminescence. 
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INTRODUCTION 
 UL are independent, clonal tumors of the uterine myometrium tissue.  
Approximately 40% of UL have nonrandom chromosomal aberrations including 
translocations and deletions.  The most common translocation, t(12;14)(q14-15;q23-24), 
is found in 20% of karyotypically abnormal tumors.  Positional cloning identified 
HMGA2 at the breakpoint in 12q14.3 (Schoenberg Fejzo, Ashar et al. 1996).  
Translocations involving HMGA2 lead to elevated expression of the gene (Gattas, Quade 
et al. 1999).  HMGA2 is an architectural factor that influences the transcription of a 
variety of genes.  It is involved in many cell processes including growth, proliferation, 
differentiation, and death so it is reasonable to conclude that overexpression of this 
protein plays a role in UL development (Grosschedl, Giese et al. 1994).  Further, a boy 
carrying an inherited, truncated variant of HMGA2 displays an overgrowth phenotype 
including a large number of lipomas (Ligon, Moore et al. 2005) which is similar to the 
phenotype of mice that also carry a truncated form of the protein (Battista, Fidanza et al. 
1999). 
 Familial and twin studies demonstrate a genetic component to UL susceptibility 
(Treloar, Do et al. 1999; Luoto, Kaprio et al. 2000).  In order to evaluate a possible role 
for HMGA2 in UL risk, a candidate gene association study was performed.  Using 248 
affected white sister-pairs, 18 markers across HMGA2 were analyzed for association to 
UL status.  One marker, in the 5’ UTR, is a TC dinucleotide repeat with approximately 
20 polymorphic human alleles ranging from 18 to 39 repeats.  Only one marker proved to 
be significantly associated with UL status as defined by a p-value<0.05 (Table 3-1).  The 
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Table 3-1.  Association results of TC dinucleotide repeat in the 5' UTR of 
HMGA2 with UL status.  Taken from Hodge, K et al. 2009. 
69
candidate marker corresponds to 27 TC repeats (p-value=0.00049) (Hodge, K et al. 
2009).  UL from women with the TC27 repeat have slightly higher HMGA2 expression 
(median = 5.39; interquartile range = [1.57, 8.58]; n=11) than UL from non-TC27 women 
(median 2.15; interquartile range = [0.08, 5.03]; n=47) which supports a role for the 
TC27 repeat in HMGA2 expression (Figure 3-1) (Hodge, K et al. 2009). 
 The HMGA2 promoter's influence on HMGA2 expression was investigated in a 
study using luciferase assays.  Fragments of the promoter lacking the TC repeat 
polymorphism exhibited significantly decreased promoter activation.  Another assay 
evaluated three contructs with the full HMGA2 promoter and TC repeat polymorphisms, 
corresponding to 1, 22, and 36 TC repeats.  Promoter activation increased with increasing 
TC repeat number (Borrmann, Seebeck et al. 2003).  These studies provide evidence for a 
role of the TC repeat polymorphism in HMGA2 expression.  However, this experiment 
used TC repeat polymorphisms not commonly found in the human population (Figure 3-
2) and did not evaluate TC27.  Additional luciferase assays are needed to explore the 
possible role of the TC27 repeat in HMGA2 expression and UL development. 
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Figure 3-1.  Real-time PCR expression results of HMGA2 from UL of white women 
with and without the TC27 repeat polymorphism.  Trend indicates higher HMGA2
expression in women with TC27 but the results are not statistically significant.  Taken 
from Hodge, K et al. 2009. 
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RESULTS 
HMGA2 promoter activation in 293T cells 
 A luciferase assay was performed to correlate TC repeat number to HMGA2
promoter activation.  Three experiments were performed, each in triplicate, with the 293T 
cell line using ten constructs of different TC repeat number, a no DNA control, an empty 
vector control and a positive control (Figure 3-3).  The empty vector control displayed 
very low promoter activation while the positive control exhibited significant activation.  
The HMGA2 promoter constructs exhibited promoter activation only slightly lower than 
the positive control.  These findings were consistent in replicates and across experiments.  
No significant difference in promoter activation was observed between the ten TC repeat 
polymorphisms in the HMGA2 promoter. 
HMGA2 promoter activation in UL and myometrium cells 
 Because we are concerned with the TC27 repeat in UL, we repeated the luciferase 
assay in normal myometrium and UL (with a t(12;14)) cell lines.  Five experiments were 
performed, each in triplicate, using three TC repeat constructs, a no DNA control, an 
empty vector control and a positive control in the myometrium cell line (UtSMC-hTERT) 
(Figure 3-4) and the UL cell line (UtLM-hTERT) (Figure 3-5).  Like the 293T cell line 
assays, the empty vector control displayed very low promoter activation compared to the 
positive control and the ratio between these controls was relatively consistent in 
replicates and between experiments.  However, unlike the 293T cell line assays, the TC 
repeat constructs show much lower promoter activation compared to the positive control 
and the ratio of the TC repeat constructs to the positive control is hugely variable 
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between replicates and across experiments.  Each experiment in both cell lines also show 
hugely variable results and differing relationships between the TC repeat constructs.  
Although replicates of the positive control and the empty vector control are relatively 
consistent and show little error, the replicates of the TC repeat plasmids have large 
variance. 
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DISCUSSION 
 Overexpression of HMGA2 is a common event in UL biology and multiple lines 
of evidence provide a link between inherited variants of HMGA2 and overgrowth 
phenotypes.  The TC27 repeat in the 5' UTR of HMGA2 is significantly associated with 
UL diagnosis and may play a role in HMGA2 expression.  A study from the Borrmann 
group (Borrmann, Seebeck et al. 2003) showed an increase in HMGA2 promoter 
activation with plasmids that contained larger TC repeats in a lipoma cell line.  I found no 
significant difference in promoter activation across ten TC repeat polymorphisms after 
three luciferase assays in 293T kidney cells.  Transcription regulation can vary by cell 
type and we were concerned that HMGA2 promoter activation in 293T cells may not be 
relevant to UL biology so the experiment was repeated in myometrium and UL cell lines. 
 After five luciferase assays in myometrium and UL cell lines, I concluded that the 
results in these cell lines were too variable to determine whether or not there is a 
difference in promoter activation between the TC repeat constructs.  The amount of 
luminescence produced from both the firefly and Renilla luciferase reporters were much 
higher in the 293T cells compared to the myometrium and UL cell lines, most likely 
indicating a higher transfection efficiency and possibly also elevated production of the 
reporters in the 293T cells.  Additionally, the luciferase activity of the HMGA2 TC repeat 
plasmids were measured at 70-90% compared to the positive control in the 293T cells 
and at less than 5% in the myometrium and UL cell lines suggesting HMGA2 promoter 
activation is regulated differently in these cell lines.  Although the total amount of 
luciferase activity was much lower in the myometrium and UL cell lines, the empty 
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vector control was still relatively consistent while the TC repeat plasmids showed hugely 
variable results between experiments and also between replicates in the same experiment.  
This result provides evidence that there is an unknown variable in the luciferase assays 
with the HMGA2 promoter plasmids in the myometrium and UL cell lines that has not 
been controlled in these experiments and that this variable was not a significant factor in 
the 293T cell assays. 
 Future work on this project will focus on developing an alternative method to 
investigate the role of the TC27 repeat on HMGA2 expression in myometrium and UL 
cell lines.  It is possible that a higher transfection efficiency will produce more robust 
results with less variation so an alternative method of transfection should be considered. 
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MATERIALS AND METHODS 
 Constructs were created using the pGL3 basic vector from Promega which 
contains the firefly luciferase gene with no promoter (Figure 3-6).  Ten constructs were 
made containing the entire 5'UTR and promoter of HMGA2 with different TC repeats 
corresponding to 20, 22, 23, 24, 25, 26, 27, 29, and 30 TC repeats.  The pRL-TK vector 
from Promega was co-transfected with the experimental constructs as an internal control.  
The pRL-TK vector encodes the Renilla luciferase gene under the control of the herpes 
simplex virus thymidine kinase promoter and produces moderate levels of Renilla 
luciferase.  A pGL3 basic vector with no promoter was used as a negative control and the 
pGL3 control vector, which contains the SV40 promoter and enhancer, was used as a 
positive control.  Constructs were transiently transfected using the Lipofectamine 2000 
kit into 293T cells, derived from human embryonic kidney cells, and into UtLM-hTERT, 
derived from a UL with a t(12;14), and UtSMC-hTERT, derived from normal 
myometrium cells.  The luciferase assay was performed using Promega’s Dual Luciferase 
Reporter Assay system and firefly and Renilla luminescence was measured 24 hours after 
transfection of the constructs.  Experiments were performed in triplicate and results are 
reported as a ratio of firefly to Renilla luminescence and normalized to the positive 
control. 
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a 
b
c 
Figure 3-6.  Schematics of a) the pGL3 basic vector used to create the 
experimental constructs, b) the pGL3-control vector used as a positive 
control, and c) the pRL-TK vector used as an internal control.
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CHAPTER 4: 
CONCLUSION 
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 In this thesis, I describe two genetic variants that associated with an increased risk 
of developing UL.  We performed the first genome-wide scan for genetic risk variants for 
UL in white women and characterized a variant previously discovered in a candidate 
gene association study.  Currently, hysterectomy is the most common treatment for UL.  
Understanding the pathways involved in UL biology is vital to develop novel, less 
invasive therapies.  Further, associating genetic variants to particular UL features, such as 
size of tumors, severity of symptoms, and age at onset, will be useful for screening.  
Genetic screening for women with a family history of UL or who already exhibit 
symptoms could facilitate family planning and aid in determining optimal treatment 
options. 
 Using genome-wide linkage and association studies, we successfully identified 
one genetic variant significantly associated with UL diagnosis.  Many limitations to these 
approaches can make it difficult to discover causal genes.  The FGFF linkage results 
uncovered seven linkage peaks with significant and suggestive LOD scores but these 
peaks are very large and contain hundreds of genes.  We have very appealing candidate 
genes for two of the peaks, HMGA2 under 12q14 and FASN at 17q25.  Variants in these 
genes have not been genotyped in the FGFF cohort at this time, therefore, we cannot 
explicitly demonstrate that these genes contribute to the linkage peaks.  An LD block 
spanning FASN is significantly associated with UL cases after a meta-analysis of two 
GWASs.  The quantile-quantile plot of the results supports this conclusion as the p-values 
of the SNPs in this LD block are much smaller than would be expected under the null 
hypothesis.  The quantile-quantile plot reveals additional SNPs with smaller p-values 
than would be expected by chance; however, they do not meet the threshold for genome-
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wide significance and cannot be considered significantly associated with UL.  Certainly, 
many true associations have been overlooked because the GWASs did not have the 
power to detect them.  Undoubtedly, a considerable amount of power was lost due to 
misclassification of controls and small sample size.  Additional samples and medically 
confirmed controls will provide the power needed to detect additional variants associated 
with UL. 
 The top, significant SNP revealed in the meta analysis is located in a large LD 
block in 17q25.3 comprising numerous SNPs located in over approximately 150 kb.  
Many SNPs in the LD block are in very high LD with the top SNP complicating location 
of the causal variant.  At this time it is difficult to conjecture about the role of the minor 
allele of this LD block in UL biology.  Of the SNPs in the LD block described by 
HapMap data, there are no variants that are likely to affect FAS protein function.  
However, there is a high probability that some of the variants fall in regulatory regions.  
It is challenging to identify a causal regulatory variant which might include SNPs that 
affect gene transcription, RNA stability and protein translation.  Further, the causal 
variant may not be described in the HapMap database and sequencing may be required to
determine it.  We found a pattern of increased FAS expression in myometrium and UL 
from women with the major allele of the top SNP compared to samples from women with 
the minor allele.  This may indicate that the causal variant affects protein expression or 
stability, however, more work is needed to identify the causal variant and determine its 
effect on FAS. 
 Three genes are located in the candidate LD block, and our functional work and 
previous research supports a role for FASN in UL biology.  Immunohistochemistry 
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results showing elevated FAS expression in UL is consistent with similar findings in 
other hormone-dependent tumors.  Overexpression of FAS in breast and prostate cancer 
has been found to be important for tumor cell survival and for this reason we believe 
FASN is a very appealing candidate gene for UL.  Inhibitors of FAS are attractive 
therapies for tumors overexpressing the protein because they seem to slow tumor 
progression with minor effects on normal cells which could mean less, more manageable 
side effects.  In the case of UL, FAS inhibitors could be the first noninvasive option for 
tumor management.  Future work will include investigating effects of FAS inhibitors on 
myometrial and UL cell lines. 
 The second part of my thesis work focused on the TC27 repeat polymorphism in 
HMGA2 that was previously found to be associated with UL diagnosis.  HMGA2 has 
been associated with UL biology through chromosomal aberrations for many years and is 
known to be overexpressed in the tumors that harbor such aberrations.  Inherited variants 
of HMGA2 have also resulted in overgrowth phenotypes, making it an appealing 
candidate for risk of developing UL.  The TC repeat in the 5'UTR of HMGA2 was found 
to contribute to promoter activation in a luciferase assay in three cell lines and increasing 
TC repeat number resulted in increased promoter activation in a lipoma cell line.  It is 
reasonable to conjecture that the TC27 repeat affects HMGA2 expression which increases 
the risk of developing UL.  Unfortunately, the method described in this thesis was not 
robust enough to evaluate the role of TC27 in the relevant myometrial and UL cell lines.  
Further work will include developing a more efficient method of transfection in the 
myometrial and UL cell lines in an effort to produce sufficient luminescence.
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 Unbiased, genome-wide studies have been very successful in uncovering genes 
associated with disorders that would not otherwise have been considered a candidate 
gene.  Herein, I have described the first risk variant of UL identified in white women by a 
genome-wide approach.  Undoubtedly, our linkage and association results harbor 
additional variants that contribute to risk for developing UL.  Moving forward, whole 
genome sequencing of cases and controls will prove to be invaluable for uncovering the 
variants contributing to our UL linkage peaks.  Sequence data will also be utilized to 
identify the causal variant in the candidate LD block at 17q25.3.  Further, studies of
additional cohorts of women with UL diagnosis and phenotypic information will increase 
the power of our meta analysis and reveal more variants with genome-wide significance 
for UL predisposition.  Identifying risk variants for UL adds to our knowledge of the 
complex biology of these tumors and brings us closer to developing novel therapies. 
